Journal article

Stereotactic Abative Body Radiotherapy (SABR) for Oligometastatic Prostate Cancer: A Prospective Clinical Trial

Shankar Siva, Mathias Bressel, Declan G Murphy, Mark Shaw, Sarat Chander, John Violet, Keen Hun Tai, Cristian Udovicich, Andrew Lim, Lisa Selbie, Michael S Hofman, Tomas Kron, Daniel Moon, Jeremy Goad, Nathan Lawrentschuk, Farshad Foroudi

EUROPEAN UROLOGY | ELSEVIER SCIENCE BV | Published : 2018

Abstract

BACKGROUND: Stereotactic ablative body radiotherapy (SABR) is an emerging treatment option for oligometastatic prostate cancer. However, limited prospective evidence is available. OBJECTIVE: To determine the safety and feasibility of single fraction SABR for patients with oligometastatic prostate cancer. Secondary endpoints were local and distant progression-free survival (LPFS and DPFS), toxicity, quality of life (QoL), and prostate-specific antigen response. DESIGN, SETTING, AND PARTICIPANTS: In a prospective clinical trial, patients were screened with computed tomography, bone scan, and sodium fluoride positron emission tomography scan and had one to three oligometastases. Kaplan-Meier me..

View full abstract